⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3955544 | 0.76 | — | — | |
| SCHEMBL23188296 | 0.75 | — | — | |
| SCHEMBL17753807 | 0.73 | — | — | |
| SCHEMBL24392680 | 0.73 | — | — | |
| SCHEMBL3858865 | 0.73 | — | — | |
| SCHEMBL22059601 | 0.73 | — | — | |
| SCHEMBL22593342 | 0.73 | — | — | |
| SCHEMBL881435 | 0.69 | — | — | |
| SCHEMBL14404687 | 0.69 | — | — | |
| SCHEMBL24548325 | 0.66 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3640247-B1 | SYK INHIBITOR AND USE METHOD THEREFOR | CHIA TAI TIANQING PHARMACEUTICAL GROUP CO LTD (CN) | 2022-01-12 | — | — | EP | disclosed |
| WO-2021064141-A1 | INHIBITORS OF DUAL SPECIFICITY TYROSINE PHOSPHORYLATION REGULATED KINASE 1B | TOLREMO THERAPEUTICS AG (CH) | 2021-04-08 | — | — | WO | disclosed |
| WO-2020216298-A1 | HDAC INHIBITOR, PREPARATION METHOD THEREFOR AND USE THEREOF | 成都先导药物开发股份有限公司 | 2020-10-29 | — | — | WO | disclosed |
| EP-3087051-B1 | BENZAMIDE AND NICOTINAMIDE COMPOUNDS AND METHODS OF USING SAME | ONCOTARTIS INC (US) | 2020-07-15 | — | — | EP | disclosed |
| EP-3640247-A1 | SYK INHIBITOR AND USE METHOD THEREFOR | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. (CN) | 2020-04-22 | — | — | EP | disclosed |
| EP-2958907-B1 | BENZOTHIOPHENE DERIVATIVES AND COMPOSITIONS THEREOF AS SELECTIVE ESTROGEN RECEPTOR DEGRADERS | NOVARTIS AG (CH) | 2018-02-28 | — | — | EP | disclosed |
| EP-2514742-A2 | Orally bioavailable cafeic acid related anticancer drugs | The Board of Regents of The University of Texas System (US) | 2012-10-24 | — | — | EP | disclosed |
| WO-2010115264-A1 | INHIBITORS OF HIV REPLICATION | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2010-10-14 | — | — | WO | disclosed |
| US-7718691-B2 | Compounds as inhibitors of hepatitis C virus NS3 serine protease | SCHERING CORPORATION (US) | 2010-05-18 | — | — | US | disclosed |
| WO-2007115269-A2 | ORALLY BIOAVAILABLE CAFFEIC ACID RELATED ANTICANCER DRUGS | THE BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM (US) | 2007-10-11 | — | — | WO | disclosed |
| US-20070049536-A1 | Novel compounds as inhibitors of hepatitis C virus NS3 serine protease | SCHERING CORPORATION | 2007-03-01 | — | — | US | disclosed |